Screener
Royalty Pharma RPRX Unfunded Commitments
Unfunded Commitments at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept rprx:ResearchAndDevelopmentUnfundedCommitments.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Product Candidates | Counterparties | Total Commitments | Funding Timing | Unfunded Commitments |
|---|---|---|---|---|
| JNJ‑4804 | Johnson & Johnson | $500,000 | Eight fixed quarterly payments commencing in the second quarter of 2026 | $437,500 |
| TEV-’408(1) | Teva Pharmaceuticals | 75,000 | Variable quarterly payments commencing in second quarter of 2026 | 65,149 |
| Litifilimab | Biogen | 250,000 | Six fixed quarterly payments commencing in first quarter of 2025 | — |
| Total | $825,000 | $502,649 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's unfunded commitments?
- Royalty Pharma (RPRX) reported unfunded commitments of $502.65M in Q2 2026.
- What does unfunded commitments mean?
- Unfunded Commitments as reported by Royalty Pharma plc Class A Ordinary Shares.
Ask your AI about Royalty Pharma's unfunded commitments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude